COVID-19, particularly in the later
complicated stages, represents and can
be managed as endothelial disease*
you could identify patients who were infected by COVID-19
as high risk for complications early?
Would you treat them differently
One of the simplest non-invasive way for assessment of Endothelial Disfunction.
FDA cleared and clinically proven as a valuable tool in cardiovascular risk stratification beyond commonly used tests.
For limited time!
we offer a unique proposal
for EndoPAT system
To receive this unique proposal please complete the form below:
*Reference: COVID-19 is, in the end, an endothelial disease, Peter Libby and Thomas Luscher, Eu-ropean Heart Journal (2020) 41, 3038–3044
** Subject to the provisions, Itamar Medical will rent per test EndoPAT Devices to the client during the defined term. $55 includes $8 EndoPAT rent fee and
$47 EndoPAT probe fee. The term should not be less than 3 months and not more than 12 months and there is a minimum of 60 probes per Endo-PAT unit
purchase requirement. This promotion valid only for US customers until April 30, 2021.